Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational Cyp11a1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
默沙東和奧里昂宣佈相互行使選擇權，向默沙東授予全球獨家使用權，用於治療轉移性去勢抵抗性前列腺癌的一種調節Cyp11a1催化劑Opevesostat的研究。